Published in Vaccine on March 01, 2014
VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science (2015) 1.91
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest (2015) 1.03
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol (2015) 0.98
Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol (2015) 0.96
Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest (2016) 0.87
pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proc Natl Acad Sci U S A (2016) 0.82
Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. PLoS One (2015) 0.80
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol (2016) 0.78
Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines (Basel) (2016) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Self-assembling peptides epitopes as a novel platform for anti-cancer vaccination. Mol Pharm (2017) 0.75
Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol (2016) 0.75
Strategies for designing synthetic immune agonists. Immunology (2016) 0.75
IL-6 Production by TLR-Activated APC Broadly Enhances Aged Cognate CD4 Helper and B Cell Antibody Responses In Vivo. J Immunol (2017) 0.75
Biologics to treat substance use disorders: Current status and new directions. Hum Vaccin Immunother (2016) 0.75
TEMPORARY REMOVAL: Synthetic nanovaccines for immunotherapy. J Control Release (2017) 0.75
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science (1972) 11.71
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature (2007) 4.88
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol (2002) 4.21
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med (1997) 4.06
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol (2003) 3.39
Immunological mechanisms of vaccination. Nat Immunol (2011) 3.35
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med (2006) 2.70
Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol (2001) 2.61
HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A (2005) 2.61
Controlled ring-opening polymerization of lactide and glycolide. Chem Rev (2004) 2.23
Bacterial DNA causes septic shock. Nature (1997) 2.19
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood (2011) 1.83
Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed (2006) 1.79
Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine (2007) 1.76
Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol (2005) 1.75
Currently approved prophylactic HPV vaccines. Expert Rev Vaccines (2009) 1.73
Vaccine adjuvants revisited. Vaccine (2007) 1.69
Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine (2010) 1.61
Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol (2007) 1.60
Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A (2009) 1.53
Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A (1999) 1.48
The control of adaptive immune responses by the innate immune system. Adv Immunol (2011) 1.48
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 1.47
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
The path to a successful vaccine adjuvant--'the long and winding road'. Drug Discov Today (2009) 1.41
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis (2007) 1.37
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res (2007) 1.33
Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A (2007) 1.28
Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 1.27
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett (2011) 1.25
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol (2006) 1.23
Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci (2011) 1.16
The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells. J Immunol (2003) 1.13
Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem (2008) 1.12
Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc (2007) 1.12
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol (2000) 1.10
Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol (2003) 1.08
Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev (2007) 1.07
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs (2009) 1.06
Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer (2007) 1.06
Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother (2003) 0.97
The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev (2009) 0.97
Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev (2009) 0.95
Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine (2004) 0.94
Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Ther Pat (2011) 0.92
HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine (2006) 0.92
Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses (2003) 0.90
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol (2006) 0.90
Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv (2006) 0.90
TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev Vaccines (2011) 0.88
Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants. Vaccine (2010) 0.86
Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob Agents Chemother (2007) 0.84
MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. J Biomed Mater Res (1999) 0.80